ALZpath Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

Proprietary ALZpath pTau217 Antibody, Utilized in Many of the Most Advanced and
Widely Available Blood Tests, Enables Early Diagnosis of Alzheimer's Disease 

ALZpath Joins the Ranks of Nvidia, YouTube, other Innovators Recognized by Fast Company

, /PRNewswire/ -- ALZpath, Inc. (ALZpath), a leading developer of diagnostic tools and solutions for Alzheimer's disease and related dementias, announced that it has been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2025.

Alzheimer's disease and related dementias are expected to impact nearly 153 million people globally by 2050. ALZpath's proprietary pTau217 antibody enables highly sensitive and accurate blood-based detection of phosphorylated tau at position 217 (pTau217), a key Alzheimer's disease biomarker, supporting early-stage diagnosis well before symptoms appear.

"It is an honor to be named one of Fast Company's World's Most Innovative Companies," said Mike Banville, CEO & President of ALZpath. "Many patients with Alzheimer's today don't have a clear diagnosis, in part because the most reliable current diagnostic methods are costly, invasive, and can only be administered at specialized facilities. Without a diagnosis, patients can't get access to the latest treatments and clinical trials. In partnership with leading diagnostic companies, ALZpath is making our best-in-class antibody for detecting Alzheimer's disease widely available in easy to administer, affordable blood tests, which we believe will vastly improve care and outcomes for millions of families facing Alzheimer's disease."

ALZpath's pTau217 antibody is already integral to the most advanced blood tests in the world, including assays being developed for clinical use by Roche, Beckman Coulter, as well as other leading tests used in research from Bio-Techne, Alamar Biosciences, and Quanterix. Notably, Roche and Beckman Coulter's pTau217 assays have received breakthrough device designation by the FDA, enabling accelerated review and the potential for widespread access in a variety of clinical settings in the U.S. and around the globe. Additionally, ALZpath partners with world-class laboratories, such as Neurocode, to further expand its reach and impact. 

"Through our licensing agreements we are empowering researchers, clinicians, and industry partners to accelerate the discovery of new treatments," said Jacob Hunter, Chief Business Officer of ALZpath. "Critically, this increased access supports the growing urgency to expand blood-based testing in research and clinical settings—enabling early identification of patients for novel treatments that have recently entered the clinical sphere, monitoring treatment response, and building robust evidence for the efficacy of novel therapies. Additionally, these efforts advance our understanding of Alzheimer's disease and validate new targeted approaches to treat and potentially prevent the disease."

This year's list shines a spotlight on businesses that are shaping industry and culture through their innovations to set new standards and achieve remarkable milestones in all sectors of the economy.

"Our list of the Most Innovative Companies offers both a comprehensive look at innovation today and a playbook for the future," said Fast Company editor-in-chief Brendan Vaughan. "This year, we recognize companies that are harnessing AI in deep and meaningful ways, brands that are turning customers into superfans by overdelivering for them, and challengers that are introducing bold ideas and vital competition to their industries. At a time when the world is rapidly shifting, these companies are charting the way forward."

The full list of Fast Company's Most Innovative Companies honorees can be found at fastcompany.com. It will also be available on newsstands beginning March 25.

About ALZpath
ALZpath is a leading developer of innovative diagnostic tools and solutions for Alzheimer's disease and related dementias. Its award-winning ALZpath pTau217 antibody, integral to the most advanced and widely available blood-based tests, is transforming Alzheimer's disease research, diagnosis, treatment and monitoring. To accelerate the development of new medicines and improve patient care for millions, ALZpath democratizes access to its proprietary antibody through licensing agreements with leading global diagnostic and research organizations. These include Roche, Beckman Coulter, Bio-Techne, Alamar Biosciences, and Quanterix. Additionally, ALZpath partners with world-class laboratories, such as Neurocode, to further expand its reach and impact. To learn more about the company, please visit https://alzpath.bio/ and follow us on LinkedIn.

About Fast Company
Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with fellow business publication Inc. For more information, please visit fastcompany.com.

ALZpath Media Contact

Nechama Rosengarten
[email protected]

SOURCE ALZpath, Inc.